• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

GenesisCare administers novel diagnostic agent Pylarify to first US patient


This video features commentary from Leonard Bitterman, the first patient in the United States to receive Pylarify (piflufolastat F 18), a novel radioactive diagnostic agent indicated for PSMA-PET imaging of lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy and men with suspected recurrence based on an elevated PSA level. Brief commentary is also provided by Kishore K. Dass, MD, a radiation oncologist at GenesisCare in Boca Raton, Florida, where Bitterman received the treatment.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.